Incyte raises 2025 product revenue guidance to $4.23-$4.32 billion; Q3 sales up 20%
Incyte reported third-quarter 2025 total revenues of $1.37 billion, up 20% from a year earlier, and GAAP net income of $424.2 million, or $2.11 per diluted share, compared with $106.5 million, or $0.54 per diluted share, in the prior-year quarter. The company raised its full-year 2025 net product revenue guidance to $4.23-$4.32 billion, while reiterating its guidance for cost of product revenues, R&D and SG&A expenses.
Key points
- Total revenues were $1.37 billion, up 20%; total net product revenues were $1.15 billion, up 19%.
- GAAP diluted EPS was $2.11 versus $0.54 a year earlier; GAAP net income was $424.2 million versus $106.5 million.
- Jakafi net product revenue rose 7% to $791 million; Opzelura rose 35% to $188 million.
- Full-year 2025 net product revenue guidance was raised to $4.23-$4.32 billion, from the prior range that the filing lists for Jakafi and other oncology products.
The filing
Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.